Drug Combo Proves Powerful Against Lung Cancer Mahopac NY

A two-drug combination treatment in Mahopac proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

Javier A Ruiz, MD
(845) 561-4450
59 New Windsor Hwy Rte 32
New Windsor, NY
MITCHELL CAIRO, MD
(212) 304-7297
38 Wrights Mill Road
Armonk, NY
Emil Hanna Wassef, MD
914-962-5151
352 Downing Dr
Yorktown Heights, NY
Dominick R Chiarieri, MD
914-241-1050
90 S Bedford Rd
Mount Kisco, NY
Robert Bruce Cooper, MD
203-792-5303
24 Hospital Ave
Danbury, CT
Umangi M Patel
(845) 561-6100
611 Gidney Ave
Newburgh, NY
JASON RUBIN, MD
(845) 231-5600
600 Westage Business Ctr Drive
Fishkill, NY
MEHMET OZKAYNAK, MD
(914) 493-7997
19 Bradhurst Avenue
Hawthorne, NY
Florencepilar M Plaza, MD
Mohegan Lake, NY
Karen Patricia Seiter, MD
914-493-8374
Rm 250 Munger Pavilion
Valhalla, NY
Data Provided by:
      

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Exercise for Prostate Cancer Mahopac NY
Regular exercise may help protect men from prostate cancer, says a new study. U.S. researchers looked at 190 men who had a prostate biopsy and found that those who were moderately active -- anything equivalent to walking at a moderate pace for several hours a week -- were significantly less likely to be diagnosed with prostate cancer.
- Hormone Therapy for Breast Cancer Mahopac NY
- Genetic Clues for Skin Cancer Therapies Mahopac NY
- Exercise for Breast Cancer Survival Mahopac NY
- Delayed Prostate Cancer Therapy Mahopac NY
- Risks for Childhood Cancer Survivors Mahopac NY
- Hormone Therapy for Lung Cancer Mahopac NY
- Fungal Infection Treatments Mahopac NY
- Side Effect Of Chemotherapy Drugs Mahopac NY